{"hands_on_practices": [{"introduction": "Effective management of hospital-acquired infections begins with astute pre-operative decision-making. A frequent and critical challenge is the evaluation of a patient's reported penicillin allergy. This exercise will guide you through the process of distinguishing a true, life-threatening IgE-mediated allergy from more common drug side effects or benign rashes, using modern immunological principles and quantitative risk assessment. By applying Bayesian reasoning to a realistic clinical vignette, you will practice making evidence-based choices for antibiotic prophylaxis, moving beyond outdated dogma about cross-reactivity. [@problem_id:5147241]", "problem": "A $62$-year-old man is scheduled for an elective total knee arthroplasty. Standard surgical prophylaxis at your institution is cefazolin. He reports a “penicillin allergy” from approximately $15$ years ago after starting oral amoxicillin for sinusitis. He recalls nausea and one episode of vomiting within a few hours of the first dose. He continued the course, and the next day developed a nonpruritic, diffuse maculopapular rash without urticaria, angioedema, bronchospasm, hypotension, or syncope. He did not seek urgent care and the rash resolved spontaneously after discontinuing the medication. He has had no exposures to any penicillin-class drugs since then. He denies any history of severe cutaneous adverse reactions such as Stevens–Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms.\n\nFrom first principles of Type I immediate hypersensitivity mediated by Immunoglobulin E (IgE), immediate reactions typically present within minutes to hours, with reproducible signs such as urticaria, angioedema, bronchospasm, hypotension, and anaphylaxis; nonimmune adverse drug reactions such as nausea and vomiting are pharmacologic side effects; delayed benign exanthems are frequently T-cell mediated and not IgE. Structural determinants of beta-lactam cross-reactivity are primarily driven by similarity of the $R_1$ side chain rather than the beta-lactam core.\n\nAssume that among surgical patients carrying a penicillin-allergy label, the prior probability of true immediate IgE-mediated penicillin allergy is $p = 0.05$. Consider a history-based clinical criterion defined as “immediate-type symptoms within $1$ hour of dosing, including urticaria, angioedema, bronchospasm, or hypotension.” For this criterion, assume sensitivity $\\text{Se} = 0.85$ and specificity $\\text{Sp} = 0.90$ for identifying true IgE-mediated allergy. In this patient, the criterion is absent.\n\nWhich option best integrates the correct classification of this patient’s past reaction, a quantitatively reasoned estimate of his post-test probability of true IgE-mediated penicillin allergy based on the provided data, an accurate explanation of cefazolin cross-reactivity with penicillins, and an appropriate management decision for perioperative prophylaxis?\n\nA. The history is most consistent with non–IgE-mediated adverse effects and a benign delayed exanthem; the estimated post-test probability of true IgE-mediated penicillin allergy is $1\\%$; cefazolin’s cross-reactivity with penicillins is $1\\%$ because cefazolin’s $R_1$ side chain is unique; proceed with cefazolin prophylaxis.\n\nB. The history is consistent with true IgE-mediated penicillin allergy; the estimated post-test probability remains approximately $5\\%$; cefazolin cross-reacts with penicillins at roughly $10\\%$ due to the shared beta-lactam ring; avoid cefazolin and use vancomycin monotherapy.\n\nC. The history is consistent with IgE-mediated penicillin allergy; the estimated post-test probability increases to approximately $40\\%$; cefazolin cross-reactivity with penicillins is negligible only after penicillin skin testing is negative; defer cefazolin unless penicillin skin testing is first performed.\n\nD. The history reflects non–IgE-mediated effects; the estimated post-test probability is approximately $3\\%$; cefazolin cross-reactivity with penicillins is $5$–$8\\%$ because beta-lactam core structures are identical; avoid cefazolin and select clindamycin for prophylaxis.", "solution": "The problem statement is internally consistent, scientifically grounded in established principles of immunology and pharmacology, and well-posed. It provides all necessary data to perform the required classification, calculation, and reasoning. Therefore, the problem is valid. The solution proceeds by systematically addressing the four required components: reaction classification, quantitative risk assessment, cross-reactivity analysis, and management decision.\n\n**1. Classification of the Patient's Past Reaction**\n\nThe patient's history from $15$ years ago describes two distinct sets of symptoms after taking oral amoxicillin.\n- **Immediate Symptoms:** Nausea and one episode of vomiting within hours of the first dose. As stated in the provided first principles, these are recognized as nonimmune adverse drug reactions, i.e., pharmacologic side effects, not signs of an allergy.\n- **Delayed Symptoms:** A diffuse, nonpruritic, maculopapular rash that appeared the next day. The problem provides that true Type I, IgE-mediated immediate hypersensitivity reactions manifest with symptoms such as urticaria (hives), angioedema, bronchospasm, or hypotension. The patient's rash was not urticarial and lacked any of these associated signs of immediate allergy. This type of delayed exanthem is characteristic of a non-IgE-mediated, likely T-cell-mediated, benign drug reaction.\n- **Conclusion:** The history is inconsistent with a true IgE-mediated penicillin allergy. It is correctly classified as a combination of pharmacologic side effects (nausea/vomiting) and a delayed, benign, non-IgE-mediated hypersensitivity reaction (maculopapular rash). The patient has a negative history for the defined clinical criterion for immediate hypersensitivity.\n\n**2. Quantitative Estimation of Post-Test Probability**\n\nWe are asked to calculate the post-test probability of a true IgE-mediated allergy given the patient's history. This is a Bayesian inference problem.\n- Let $D^+$ be the event that the patient has a true IgE-mediated penicillin allergy.\n- Let $D^-$ be the event that the patient does not have a true IgE-mediated penicillin allergy.\n- Let $T^+$ be the event that the clinical criterion for immediate allergy is present, and $T^-$ be the event that it is absent.\n\nThe provided data are:\n- Prior probability of true allergy: $P(D^+) = p = 0.05$.\n- Sensitivity of the criterion: $\\text{Se} = P(T^+|D^+) = 0.85$.\n- Specificity of the criterion: $\\text{Sp} = P(T^-|D^-) = 0.90$.\n\nFrom this, we can derive:\n- The probability of not having a true allergy: $P(D^-) = 1 - P(D^+) = 1 - 0.05 = 0.95$.\n- The probability of a negative test given a true allergy (false negative rate): $P(T^-|D^+) = 1 - \\text{Se} = 1 - 0.85 = 0.15$.\n\nThe patient's history is negative for the criterion, so we need to calculate the posterior probability $P(D^+|T^-)$. Using Bayes' theorem:\n$$ P(D^+|T^-) = \\frac{P(T^-|D^+)P(D^+)}{P(T^-)} $$\nThe denominator, $P(T^-)$, is the total probability of a negative test result, calculated using the law of total probability:\n$$ P(T^-) = P(T^-|D^+)P(D^+) + P(T^-|D^-)P(D^-) $$\nSubstituting the known values:\n$$ P(T^-) = (0.15)(0.05) + (0.90)(0.95) $$\n$$ P(T^-) = 0.0075 + 0.855 = 0.8625 $$\nNow we can calculate the post-test probability:\n$$ P(D^+|T^-) = \\frac{0.0075}{0.8625} \\approx 0.0086956... $$\nExpressed as a percentage, the post-test probability is approximately $0.87\\%$. This value is less than $1\\%$.\n\n**3. Cefazolin Cross-Reactivity with Penicillins**\n\nThe problem explicitly states a key principle: \"Structural determinants of beta-lactam cross-reactivity are primarily driven by similarity of the $R_1$ side chain rather than the beta-lactam core.\" This is the modern, accepted understanding.\n- The patient's historical reaction was to amoxicillin.\n- The proposed prophylaxis is cefazolin, a first-generation cephalosporin.\n- Amoxicillin and cefazolin have structurally dissimilar $R_1$ side chains.\n- Therefore, based on the provided principle, the risk of IgE-mediated cross-reactivity between amoxicillin and cefazolin is very low. Modern evidence-based guidelines place this risk at less than $1\\%$. The older notion of a $5\\%-10\\%$ cross-reactivity rate was based on early studies with penicillin-contaminated cephalosporin preparations and an incorrect emphasis on the shared beta-lactam ring as the primary antigenic determinant for all cross-reactions.\n\n**4. Appropriate Management Decision**\n\nThe comprehensive analysis leads to the following conclusions:\n- The patient's reported \"allergy\" is, by clinical history, not a dangerous IgE-mediated reaction.\n- The quantitative post-test probability of the patient having a true, undiagnosed IgE-mediated allergy is very low ($1\\%$).\n- The risk of an IgE-mediated cross-reaction to cefazolin is also very low ($1\\%$) due to dissimilar $R_1$ side chains.\n\nCefazolin is the recommended first-line agent for surgical prophylaxis for total knee arthroplasty due to its optimal spectrum of activity against common skin flora (e.g., *Staphylococcus aureus*, streptococci) and proven efficacy. Avoiding it in favor of second-line agents like vancomycin or clindamycin introduces other risks, such as less optimal coverage, higher toxicity, and increased risk of *Clostridioides difficile* infection. Given the extremely low overall risk of a clinically significant allergic reaction to cefazolin in this patient, the most appropriate and evidence-based management decision is to proceed with the standard prophylactic agent, cefazolin.\n\n**Evaluation of Options**\n\n**A. The history is most consistent with non–IgE-mediated adverse effects and a benign delayed exanthem; the estimated post-test probability of true IgE-mediated penicillin allergy is $1\\%$; cefazolin’s cross-reactivity with penicillins is $1\\%$ because cefazolin’s $R_1$ side chain is unique; proceed with cefazolin prophylaxis.**\n- **Reaction Classification:** Correct.\n- **Post-test Probability:** Correct. The calculated probability is $\\approx 0.87\\%$, which is $1\\%$.\n- **Cross-reactivity:** Correct. The reasoning (dissimilar $R_1$ side chain implies low cross-reactivity) and the quantitative estimate ($1\\%$) are accurate.\n- **Management:** Correct. This represents the standard of care based on a sound risk-benefit analysis.\n- **Verdict:** **Correct**.\n\n**B. The history is consistent with true IgE-mediated penicillin allergy; the estimated post-test probability remains approximately $5\\%$; cefazolin cross-reacts with penicillins at roughly $10\\%$ due to the shared beta-lactam ring; avoid cefazolin and use vancomycin monotherapy.**\n- **Reaction Classification:** Incorrect. The history lacks features of an IgE-mediated reaction.\n- **Post-test Probability:** Incorrect. A negative test result must lower the prior probability; it does not remain the same. The calculation confirms a significant decrease.\n- **Cross-reactivity:** Incorrect. This invokes an outdated mechanism (beta-lactam core) and an inflated, obsolete rate ($10\\%$).\n- **Management:** Incorrect. This decision is overly cautious and not evidence-based.\n- **Verdict:** **Incorrect**.\n\n**C. The history is consistent with IgE-mediated penicillin allergy; the estimated post-test probability increases to approximately $40\\%$; cefazolin cross-reactivity with penicillins is negligible only after penicillin skin testing is negative; defer cefazolin unless penicillin skin testing is first performed.**\n- **Reaction Classification:** Incorrect.\n- **Post-test Probability:** Incorrect. The probability *decreases* with a negative test, it does not increase. The value of $40\\%$ is arithmetically baseless for this scenario.\n- **Cross-reactivity:** Incorrect. The cross-reactivity is inherently low due to chemical structure, not contingent on skin testing, though a negative test would provide further reassurance.\n- **Management:** Incorrect. Deferring the standard of care for mandatory testing is not indicated in such a low-risk situation.\n- **Verdict:** **Incorrect**.\n\n**D. The history reflects non–IgE-mediated effects; the estimated post-test probability is approximately $3\\%$; cefazolin cross-reactivity with penicillins is $5$–$8\\%$ because beta-lactam core structures are identical; avoid cefazolin and select clindamycin for prophylaxis.**\n- **Reaction Classification:** Correct.\n- **Post-test Probability:** Incorrect. The calculated value is $\\approx 0.87\\%$, not $3\\%$.\n- **Cross-reactivity:** Incorrect. The mechanism is wrong (it's the $R_1$ side chain, not the core), and the rate of $5$–$8\\%$ is an outdated overestimation.\n- **Management:** Incorrect. This is an overly cautious decision based on flawed risk assessment.\n- **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "5147241"}, {"introduction": "Once an appropriate antibiotic like cefazolin is selected, the next step is to ensure it remains effective for the entire duration of the surgical procedure. This practice problem focuses on the core principles of pharmacokinetics that govern antibiotic dosing. You will use concepts like drug half-life ($t_{1/2}$) and first-order elimination to calculate a weight-based dose and determine a rational intraoperative redosing interval, ensuring the drug concentration stays above the minimum effective level. This exercise sharpens quantitative reasoning and solidifies the crucial link between pharmacological theory and its practical application in the operating room. [@problem_id:5147314]", "problem": "A surgical prophylaxis protocol for an adult undergoing a clean-contaminated abdominal operation uses cefazolin to prevent surgical site infections, a common hospital-acquired infection in surgical patients. Institutional policy is to administer a weight-based cefazolin dose of $2\\,\\text{g}$ for patients with body weight $120\\,\\text{kg}$ and $3\\,\\text{g}$ for patients with body weight $\\ge 120\\,\\text{kg}$. Consider a patient weighing $130\\,\\text{kg}$ with normal renal function. Assume cefazolin exhibits one-compartment, first-order elimination in this patient, with a terminal half-life $t_{1/2} = 1.8\\,\\text{h}$. Immediately after distribution of the initial dose, the free tissue concentration of cefazolin is $4$ times the minimum effective concentration (MEC), which for this purpose equals the minimum inhibitory concentration (MIC) for the expected organisms. Blood loss is $500\\,\\text{mL}$ and fluid shifts are negligible, so elimination kinetics are not altered during the case. Define the intraoperative redosing time as the first time $t$ at which, if no redose were given, the free tissue concentration would decline to the MEC. Redose with the same mass as the initial dose at that time and at equal subsequent intervals, provided the scheduled redose time occurs strictly before the end of surgery. The initial dose is administered at incision time $t=0$. The operation lasts $8.0\\,\\text{h}$ from completion of the initial infusion to skin closure.\n\nUsing only fundamental pharmacokinetic principles of first-order elimination and the definition of half-life, determine:\n- (i) the per-dose mass in milligrams based on the weight-based rule,\n- (ii) the intraoperative redosing interval in hours implied by the above definition,\n- (iii) the total mass of cefazolin administered over the case.\n\nExpress your final answer as a single number equal to the total mass administered, in milligrams. No rounding is required; report a whole number of milligrams.", "solution": "The problem will be validated by first extracting the given information and then assessing its scientific validity, consistency, and structure.\n\n### Step 1: Extract Givens\n- **Patient Weight**: $130\\,\\text{kg}$\n- **Drug**: Cefazolin for surgical prophylaxis.\n- **Dosing Rule**: $2\\,\\text{g}$ for patient weight $ 120\\,\\text{kg}$; $3\\,\\text{g}$ for patient weight $\\ge 120\\,\\text{kg}$.\n- **Pharmacokinetic Model**: One-compartment, first-order elimination.\n- **Terminal Half-Life ($t_{1/2}$)**: $1.8\\,\\text{h}$\n- **Initial Condition**: At $t=0$ (immediately after distribution of the initial dose), the free tissue concentration $C(0)$ is $4$ times the minimum effective concentration (MEC). So, $C(0) = C_0 = 4 \\times \\text{MEC}$.\n- **Redosing Trigger**: The free tissue concentration declines to the MEC.\n- **Redosing Interval Definition**: The time $\\tau$ at which $C(\\tau) = \\text{MEC}$. Subsequent redoses occur at integer multiples of this interval.\n- **Redosing Condition**: A redose is administered only if its scheduled time is strictly before the end of surgery.\n- **Initial Dose Time**: $t=0$.\n- **Total Surgery Duration ($T_{op}$)**: $8.0\\,\\text{h}$.\n- **Assumption**: Elimination kinetics are constant throughout the surgery.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem is scientifically sound. It describes a standard clinical application of pharmacokinetics. Cefazolin is a common prophylactic antibiotic, the one-compartment model with first-order elimination is a fundamental approximation, the half-life of $1.8\\,\\text{h}$ is clinically accurate for a patient with normal renal function, and weight-based dosing is a standard practice. The core principle of maintaining concentrations above the MEC/MIC is central to antibiotic therapy.\n2.  **Well-Posed**: The problem is well-posed. It provides all necessary information to determine the requested quantities, and the definitions lead to a unique, stable, and meaningful solution.\n3.  **Objective**: The language is precise, quantitative, and free of subjectivity.\n4.  **Complete and Consistent**: The provided data are sufficient and not contradictory. The patient's weight of $130\\,\\text{kg}$ unambiguously determines the dose. The definition of the redosing interval is clear. The duration of the operation and the condition for redosing are explicitly stated.\n5.  **Realistic and Feasible**: The scenario and all numerical values are realistic within a clinical context.\n\n### Step 3: Verdict and Action\nThe problem is valid. A reasoned solution will be provided.\n\n### Solution\nThe problem requires the determination of three quantities, culminating in the total mass of cefazolin administered.\n\n**(i) Per-dose mass in milligrams:**\nThe patient's body weight is given as $130\\,\\text{kg}$. The institutional policy dictates a dose of $2\\,\\text{g}$ for patients with weight $ 120\\,\\text{kg}$ and $3\\,\\text{g}$ for patients with weight $\\ge 120\\,\\text{kg}$. Since $130\\,\\text{kg} \\ge 120\\,\\text{kg}$, the patient qualifies for the higher dose.\nLet $M_{dose}$ be the mass of cefazolin per dose.\n$$M_{dose} = 3\\,\\text{g}$$\nThe problem requests the final answer in milligrams. We convert grams to milligrams knowing that $1\\,\\text{g} = 1000\\,\\text{mg}$.\n$$M_{dose} = 3\\,\\text{g} \\times \\frac{1000\\,\\text{mg}}{1\\,\\text{g}} = 3000\\,\\text{mg}$$\n\n**(ii) Intraoperative redosing interval:**\nThe elimination of cefazolin follows first-order kinetics. The concentration of the drug, $C(t)$, at time $t$ after a dose is given by the equation:\n$$C(t) = C_0 \\exp(-k_e t)$$\nwhere $C_0$ is the initial concentration at $t=0$ and $k_e$ is the first-order elimination rate constant.\n\nThe half-life, $t_{1/2}$, is defined as the time required for the concentration to decrease to half of its initial value. This relationship is expressed as:\n$$\\frac{C_0}{2} = C_0 \\exp(-k_e t_{1/2})$$\n$$\\frac{1}{2} = \\exp(-k_e t_{1/2})$$\nTaking the natural logarithm of both sides gives:\n$$\\ln\\left(\\frac{1}{2}\\right) = -k_e t_{1/2}$$\n$$-\\ln(2) = -k_e t_{1/2}$$\nThis allows us to express the elimination rate constant $k_e$ in terms of the given half-life $t_{1/2}$:\n$$k_e = \\frac{\\ln(2)}{t_{1/2}}$$\n\nThe problem defines the initial concentration as $C_0 = 4 \\times \\text{MEC}$. The redosing interval, which we denote as $\\tau$, is the time at which the concentration drops to the MEC. We set $t = \\tau$ and $C(\\tau) = \\text{MEC}$ in the concentration decay equation:\n$$C(\\tau) = C_0 \\exp(-k_e \\tau)$$\n$$\\text{MEC} = (4 \\times \\text{MEC}) \\exp(-k_e \\tau)$$\nDividing by MEC (which is non-zero) yields:\n$$1 = 4 \\exp(-k_e \\tau)$$\n$$\\frac{1}{4} = \\exp(-k_e \\tau)$$\nTaking the natural logarithm of both sides:\n$$\\ln\\left(\\frac{1}{4}\\right) = -k_e \\tau$$\n$$-\\ln(4) = -k_e \\tau$$\n$$\\ln(4) = k_e \\tau$$\nSolving for $\\tau$:\n$$\\tau = \\frac{\\ln(4)}{k_e} = \\frac{\\ln(2^2)}{k_e} = \\frac{2\\ln(2)}{k_e}$$\nNow, we substitute the expression for $k_e$ in terms of $t_{1/2}$:\n$$\\tau = \\frac{2\\ln(2)}{\\frac{\\ln(2)}{t_{1/2}}} = 2 \\, t_{1/2}$$\nThe redosing interval is exactly two half-lives. Given $t_{1/2} = 1.8\\,\\text{h}$:\n$$\\tau = 2 \\times 1.8\\,\\text{h} = 3.6\\,\\text{h}$$\n\n**(iii) Total mass of cefazolin administered:**\nThe initial dose is administered at incision time, $t=0$. The total duration of the operation is $T_{op} = 8.0\\,\\text{h}$.\nRedoses are given at intervals of $\\tau = 3.6\\,\\text{h}$, provided the scheduled time of administration is strictly less than the end of surgery time, $T_{op}$.\n\nLet's list the administration times:\n- Initial dose: $t_0 = 0\\,\\text{h}$. This dose is given.\n- First redose: $t_1 = t_0 + \\tau = 0 + 3.6\\,\\text{h} = 3.6\\,\\text{h}$. Since $3.6\\,\\text{h}  8.0\\,\\text{h}$, this dose is administered.\n- Second redose: $t_2 = t_1 + \\tau = 3.6\\,\\text{h} + 3.6\\,\\text{h} = 7.2\\,\\text{h}$. Since $7.2\\,\\text{h}  8.0\\,\\text{h}$, this dose is also administered.\n- Third redose: $t_3 = t_2 + \\tau = 7.2\\,\\text{h} + 3.6\\,\\text{h} = 10.8\\,\\text{h}$. Since $10.8\\,\\text{h} \\not 8.0\\,\\text{h}$, this dose is not administered.\n\nThe total number of doses administered, $N_{doses}$, is $3$ (one initial dose and two redoses).\nThe mass of each dose is $M_{dose} = 3000\\,\\text{mg}$.\nThe total mass administered, $M_{total}$, is the product of the number of doses and the mass per dose:\n$$M_{total} = N_{doses} \\times M_{dose}$$\n$$M_{total} = 3 \\times 3000\\,\\text{mg} = 9000\\,\\text{mg}$$\nThe total mass of cefazolin administered over the case is $9000\\,\\text{mg}$.", "answer": "$$\\boxed{9000}$$", "id": "5147314"}, {"introduction": "The responsibility for managing hospital-acquired infections extends from individual patient care to the systematic evaluation of a surgical service's performance. This final hands-on practice introduces the Standardized Infection Ratio (SIR), a cornerstone metric in healthcare epidemiology and quality improvement. You will learn how to calculate the expected number of infections for a diverse group of surgical patients by using established, risk-adjusted baseline probabilities. By comparing this expected value to the observed number of infections, you will compute an SIR, gaining experience with the fundamental tools used to monitor, benchmark, and improve infection prevention efforts at an institutional level. [@problem_id:5147227]", "problem": "A tertiary surgical service evaluating hospital-acquired infections seeks to compute an overall measure of risk-adjusted performance for surgical site infections using the Standardized Infection Ratio (SIR). The Standardized Infection Ratio (SIR) is a widely used epidemiologic ratio comparing the number of observed infections to the number expected under risk-adjusted baseline conditions. The expected number of infections is derived from the sum of patient-level infection probabilities based on risk-adjusted baseline data, such as those published by the National Healthcare Safety Network (NHSN). Use the following principles and data to construct the SIR from first principles.\n\nFoundational base to use:\n- For a series of patients indexed by $i = 1, 2, \\dots, n$, define a Bernoulli random variable $X_i$ that equals $1$ if the patient develops a surgical site infection and $0$ otherwise. For each patient $i$, suppose the risk-adjusted baseline probability of infection is $p_i \\in [0,1]$. The expected number of infections across the cohort is the sum of patient-level expectations, which by linearity of expectation equals $\\sum_{i=1}^{n} p_i$.\n- The Standardized Infection Ratio is defined as the ratio of observed infections to expected infections derived from the baseline risk model.\n\nA single quarter’s surgical cohort comprises three procedure categories with case-mix distributions specified by American Society of Anesthesiologists (ASA) physical status class and procedure duration relative to the $75$th percentile for the category. For each category, the risk-adjusted baseline probability of surgical site infection is given for each stratum. All baseline probabilities are derived from a validated risk model consistent with National Healthcare Safety Network (NHSN) methods. Use the data below to compute the expected infections and then the overall SIR, aggregating across all procedure categories.\n\nColon resection (COLO), $50$ procedures:\n- Clean-contaminated, ASA $2$, duration $\\leq$ $75$th percentile: $n = 28$, baseline $p = 0.045$.\n- Clean-contaminated, ASA $3$, duration $\\leq$ $75$th percentile: $n = 12$, baseline $p = 0.065$.\n- Contaminated, ASA $3$, duration $$ $75$th percentile: $n = 7$, baseline $p = 0.140$.\n- Dirty/infected, ASA $4$, duration $$ $75$th percentile: $n = 3$, baseline $p = 0.230$.\nObserved infections in COLO category: $6$.\n\nHip prosthesis (HPRO), $40$ procedures:\n- Clean, ASA $2$, duration $\\leq$ $75$th percentile: $n = 20$, baseline $p = 0.012$.\n- Clean, ASA $3$, duration $\\leq$ $75$th percentile: $n = 10$, baseline $p = 0.018$.\n- Clean, ASA $3$, duration $$ $75$th percentile: $n = 6$, baseline $p = 0.026$.\n- Clean, ASA $4$, duration $$ $75$th percentile: $n = 4$, baseline $p = 0.041$.\nObserved infections in HPRO category: $1$.\n\nPeripheral vascular bypass (PVBY), $30$ procedures:\n- Clean-contaminated, ASA $3$, duration $\\leq$ $75$th percentile: $n = 15$, baseline $p = 0.055$.\n- Clean-contaminated, ASA $3$, duration $$ $75$th percentile: $n = 10$, baseline $p = 0.085$.\n- Clean-contaminated, ASA $4$, duration $$ $75$th percentile: $n = 5$, baseline $p = 0.120$.\nObserved infections in PVBY category: $3$.\n\nUsing only the principles stated above, derive the expected number of infections for each procedure category and in total by summing $p$ across all patients in each stratum. Then compute the overall SIR for surgical site infections across the aggregated cohort of $120$ procedures as the ratio of total observed infections to total expected infections. Express the final answer as a single real number, rounded to four significant figures. Do not use the percent sign; the answer is a unitless ratio.", "solution": "The problem is confirmed to be scientifically sound and well-posed, with all necessary data provided. The solution involves calculating the total number of observed infections, calculating the total number of expected infections by summing the contributions from each stratum, and then computing their ratio.\n\n**Step 1: Calculate the Total Number of Observed Infections**\nThe total number of observed infections ($N_{obs}$) is the sum of the observed infections from each of the three procedure categories.\n- Observed infections in Colon resection (COLO): $6$\n- Observed infections in Hip prosthesis (HPRO): $1$\n- Observed infections in Peripheral vascular bypass (PVBY): $3$\n\n$$ N_{obs} = 6 + 1 + 3 = 10 $$\n\n**Step 2: Calculate the Total Number of Expected Infections**\nThe total number of expected infections ($N_{exp}$) is the sum of the expected infections for each category. The expected number for each category is calculated by multiplying the number of patients ($n$) in each risk stratum by the corresponding baseline probability of infection ($p$) and summing these products.\n\n**Expected Infections for Colon Resection (COLO):**\n$$ E_{COLO} = (28 \\times 0.045) + (12 \\times 0.065) + (7 \\times 0.140) + (3 \\times 0.230) $$\n$$ E_{COLO} = 1.26 + 0.78 + 0.98 + 0.69 = 3.71 $$\n\n**Expected Infections for Hip Prosthesis (HPRO):**\n$$ E_{HPRO} = (20 \\times 0.012) + (10 \\times 0.018) + (6 \\times 0.026) + (4 \\times 0.041) $$\n$$ E_{HPRO} = 0.24 + 0.18 + 0.156 + 0.164 = 0.74 $$\n\n**Expected Infections for Peripheral Vascular Bypass (PVBY):**\n$$ E_{PVBY} = (15 \\times 0.055) + (10 \\times 0.085) + (5 \\times 0.120) $$\n$$ E_{PVBY} = 0.825 + 0.85 + 0.60 = 2.275 $$\n\n**Total Expected Infections ($N_{exp}$):**\n$$ N_{exp} = E_{COLO} + E_{HPRO} + E_{PVBY} $$\n$$ N_{exp} = 3.71 + 0.74 + 2.275 = 6.725 $$\n\n**Step 3: Calculate the Standardized Infection Ratio (SIR)**\nThe SIR is the ratio of the total observed infections to the total expected infections.\n$$ \\text{SIR} = \\frac{N_{obs}}{N_{exp}} = \\frac{10}{6.725} \\approx 1.4870 $$\n\n**Step 4: Round to Four Significant Figures**\nThe calculated SIR, $1.4870$, rounded to four significant figures is $1.487$.", "answer": "$$\n\\boxed{1.487}\n$$", "id": "5147227"}]}